bedridden long
upgrad overweight
despit improv hillrom lag peer
pt ytd trade turn discount movement
digit pipelin emerg market invest
well understood creat attract disconnect upgrad
better profil higher multipl bia hillrom inch higher recent
quarter see pipelin connect care contribut drove
pt pt organ growth acceler improv
went unrequit hillrom lag peer pt linger confus
growth reconcili concern compani still reliant bed
 centrella see acceler momentum
given shift digital/ connect care pipelin product drive
balanc growth across segment emerg market invest
recognit durabl organ growth profil narrow
turn discount peer faster ebitda growth support doubl digit ep
old new investor focus hillrom
tradit busi appear appreci three invest area
transform organ growth fact growth improv
investor question sustain centrella
signific driver grow contribut point
growth versu expect bp see lsd-msd
centrella growth guidanc prudent perhap conserv focu
upgrad new invest driver real quantifi like
well understood street
digit connect busi includ
voalt see grow drive bp
corpor growth year digit go hillrom
pipelin see exhibit drove pt growth see
product base continu drive pt growth relat
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
add-on new product launch drive pt growth annual
emerg market repres revenu today see em
grow faster given ceo john groetelaar
recent initi replac manag refocu growth em growth
drive bp bp growth model
told see path durabl msd growth driver contribut
pt organ growth assum remain hillrom grow low-
end compani wamgr visibl growth much better
consensu multipl assum expect growth shift becom
appar across balanc drive multipl expans exhibit
show hillrom valuat discount smid peer rel growth profil
margin offer upsid flexibl invest hillrom demonstr
consist abil drive margin expans averag bp per annum
last five year despit hillrom lrp impli om/gm ratio
in-lin peer sit today bp ebit
expans reach guidanc look conserv vs mse bp
continu see opportun hillrom deliv bp per year
upsid reinvest growth recent issu lrp lay
om impli bp annual om expans sens
digit recent vision product launch spotvis retinavu
respiratori portfolio monarch breath math
collect becom revenu could impli gm
guidanc conserv model in-lin lrp guidanc gm
level bp ahead om drive ep compound-annual-growth-rate street-high
earn lrp
portfolio manag move wamgr hillrom weight averag
market growth rate wamgr recent action divest declin
segment acquir higher growth asset risk-adjust recip success
creat valu peer includ
whose wamgr start low singl digit deal prior manag
mix follow differ script recent surgic consum
divestitur busi declin lsd annual breath voalt
acquisit expect contribut grow
strong double-digit asset swap like pt accret organ
growth hillrom capac deploy net debt
ebitda think plausibl expect tuck-in
rang next includ lrp see
lrp thought digital/ care commun manag greatest area
interest invest multipl accret note
knowledg potenti transact
could wrong emerg market china could grow slower
given weaker execut geopolit issu tariff escal imb
tariff impact hospit capit budget compress
elect year hospit survey still reflect elev spend
bed competitor make inroad smart medsurg bed launch
note us medsurg instal base penetr
better buy organ especi discount rais pt
hillrom lag given concern reconcili poor
comprehens novel growth driver lead lack confid
sustain growth organ growth clear path acceler
momentum acceler alreadi evid stock look
inexpens ev/ebitda vs smid peer rais price
target reflect ebitda multipl support dcf
valuat major assumpt includ wacc termin
growth rate peak margin multiple-bas target reflect
discount peer move past non-cor dynam digit solut
continu contribut emerg market show improv
discount could narrow
discount narrow hillrom drive durabl msd growth
discount
narrow hillrom drive durabl msd growth
price target reflect ev/ebitda multipl
ebitda discount smid peer given slightli lower growth
bull case ebitda
bull case ebitda
new product growth intern exceed expect cost initi
take margin higher new product launch contribut bp annual
growth margin expans surpass lrp driven revenu upsid mix
cost initi manag remain focus addit deal shift
base case ebitda
base case ebitda
growth stabil mid-singl digit pipelin product move hill-rom
structur organ growth rate msd beyond compani
execut lrp emerg market inflect greater recognit growth
stabil visibl margin improv drive multipl higher
bear case ebitda
bear case ebitda
long-term plan materi organ growth remain lsd
slowdown capital-expenditure environ hurt pss pipelin fail
materi expect initi manifest plan along
top-line shortfal drive limit margin improv
multipl fall lrp fail materi
hill-rom multipl re-rat
growth move higher volatil
decreas hillrom revenu base
diversifi digit new product
launch em penetr drive
hill-rom growth rate durabl
hillrom new lrp call growth
annual om
expans ep compound-annual-growth-rate see
new lrp achiev given product
pipelin remain robust end market
mix digit improv lift margin
hospit budget risk consider
elect year recent alphawis
contribut sale
togeth new launch drive
increment revenu year
lrp
shift connect ecosystem
busi grow strong double-digit
emerg market penetr em
hillrom revenu today ceo john
groetelaar focus drive greater
penetr focus sale
 deal shift wamgr higher
progress cost restructur
risk achiev price
pipelin traction slow fail
materi upcom product
margin leverag prove difficult
materi shift capital-expenditure environ
path durabl msd growth
centrella bed famili includ centrella medsurg bed envella accella icu
bed like contribut revenu pt growth view
manag guidanc lsd-msd growth drive bp corpor
growth prudent given visibl solid order book enter year us
instal base medsurg bed still msd penetr centrella
although new medsurg bed launch see room
sustain smart-b penetr compani given vast major us
hospit yet upgrad last major replac cycl early-
centrella famili deliv solid msd growth could see
addit corpor growth lsd growth would impli bp
corpor
commun poorli understood street
underappreci implic growth multipl sens
busi includ voalt grow assum
segment continu grow impli
revenu respect alon drive pt organ growth digit
increasingli import focu manag given high growth partli recur
revenu natur would surpris see addit acquisit
strengthen segment
vision respiratori launch drive flc within front line vision vision
retinavu vital sign connex respiratori product monarch
doubl digit grower like continu grow double-digit averag throughout
togeth drive bp corpor growth model
bp sens breath becom organ septemb
see minim revenu earli ramp drive bp growth
recent ss product launch off-set oem wind-down integr tabl
motion intuit da vinci si ile surgic ts surgic tabl
collect bp growth next two fiscal year
contribut off-set intern oem busi wind-
bp bp hit corpor organ growth respect
consid new product contribut hillrom plan launch sever new product
add-on recent launch product year guidanc call
pt annual organ growth contribut product collect
expect product launch busi segment least one new
digit offer sum new add-on product recent launch discuss
see pt annual growth increment contribut year
lrp
 em hillrom show earli evid intern growth
turnaround expect improv even
compani face headwind year surgic oem wind-
em repres compani today grew hsd exit ceo john
groetelaar built em busi bard sinc join hillrom replac emea
leadership implement focus sale strategi see dd em
growth rel hsd guidanc could see increment bp
corpor growth em grow would drive pt growth
valuat implic net model reflect organ growth re-acceler
beyond question worth exhibit show hillrom
ev/ebitda sale growth profil rel smid peer hillrom trade
discount median ev ebitda top-line growth profil rel
peer grow slight discount remain appropri view given hillrom
lower growth profil importantli hillrom growth becom durabl
see upsid growth forecast driver list becom greater
percentag total revenu note higher multipl worth share
price perform
consensu number reflect
valuat methodolog risk associ recommend rate price target referenc report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
integr tabl motion da vinci xi
product contribut
driver
impact corpor
dollar million except per share data
total revenu
less net incom non-controlling interest
net incom sharehold
dollar million except per share data
dollar million except per share data
invest invest secur
softwar net
note receiv net discount
accru pension postretir benefit
addit paid capit
dollar million except per share data
net realiz capit loss gain equiti method invest incom loss
provis defer incom tax
chang oper asset liabil
net provid oper activ
capit expenditur purchas intang
proce dispos properti equip leas
proce sale non-strateg asset
payment acquisit busi net cash
invest purchas capit call
proce invest sale matur
net use invest activ
net chang short-term debt net debt issuanc cost
payment long-term debt net proce settlement interest rate swap includ payment/borrow revolv
distribut non-controlling interest partner
net chang equiti
effect exchang rate ce
net chang
equival bop
equival eop
